Compare FOXX & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOXX | HOTH |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 18.0M |
| IPO Year | N/A | 2019 |
| Metric | FOXX | HOTH |
|---|---|---|
| Price | $4.57 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | ★ 2.7M | 276.6K |
| Earning Date | 11-18-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $63,030,415.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 139.29 | N/A |
| 52 Week Low | $1.71 | $0.66 |
| 52 Week High | $11.00 | $3.80 |
| Indicator | FOXX | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.39 | 44.22 |
| Support Level | $1.71 | $1.14 |
| Resistance Level | $6.90 | $1.24 |
| Average True Range (ATR) | 0.89 | 0.08 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 54.12 | 65.29 |
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).